Citius Oncology, the oncology division of Citius Pharmaceuticals, entered into an exclusive distribution agreement with Uniphar to supply its FDA‑approved drug LYMPHIR outside the United States. The partnership designates Uniphar as the sole distributor in selected Western and Eastern European territories, where the company will manage market access through country‑specific managed access programs.
The deal represents Citius Oncology’s third international distribution partnership and is part of a broader strategy to expand LYMPHIR’s reach. Because LYMPHIR has not yet received commercial approval in Europe, the agreement will enable early patient access through managed access programs while the company pursues regulatory submissions in those markets.
Leonard Mazur, Chairman and CEO, said the partnership “builds on the momentum of our international expansion efforts and reflects our commitment to partnering with experienced organizations that have deep regional expertise.” He added that the agreement “further strengthens our ability to responsibly expand access to LYMPHIR.”
LYMPHIR, an engineered IL‑2‑diphtheria toxin fusion protein, received FDA approval in August 2024 for relapsed or refractory cutaneous T‑cell lymphoma (CTCL). The approval marked the first new systemic therapy for CTCL in more than six years and positioned LYMPHIR as a key treatment option in a market that exceeds $400 million in the United States and is projected to grow globally.
Citius Pharmaceuticals has invested heavily in research and development, reporting R&D expenses of $9.2 million and general and administrative expenses of $18.5 million for the fiscal year ended September 30 2025. The company’s cash and cash equivalents stood at $4.3 million. In Q4 2025, the company posted an earnings per share of –$0.11, beating analyst expectations of –$0.24, a result attributed to disciplined cost management amid ongoing R&D investments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.